Morgan Stanley Ascendis Pharma A/S Transaction History
Morgan Stanley
- $1.39 Trillion
- Q4 2024
A detailed history of Morgan Stanley transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Morgan Stanley holds 825,761 shares of ASND stock, worth $119 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
825,761
Previous 312,488
164.25%
Holding current value
$119 Million
Previous $46.7 Million
143.61%
% of portfolio
0.01%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding ASND
# of Institutions
236Shares Held
59.6MCall Options Held
108KPut Options Held
234K-
Ra Capital Management, L.P. Boston, MA10.1MShares$1.46 Billion22.55% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.53MShares$797 Million3.52% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.1MShares$735 Million10.24% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.45MShares$641 Million0.98% of portfolio
-
Janus Henderson Group PLC London, X04.38MShares$631 Million0.32% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $8.04B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...